Abstract 106P
Background
Chemotherapy-induced toxicities lead to therapy dose reduction or delay, affecting patient outcomes. This real-world study retrospectively evaluated the impact of relative dose intensity (RDI) on survival in advanced colorectal cancer patients treated with 5-FU-based regime as first-line chemotherapy.
Methods
We identified 253 eligible patients with advanced CRC who received 5-FU based first-line chemotherapy. The study protocol was submitted to the institutional review board and was exempted. Dose delay was defined as an average delay of more than 3 days (>3 days vs. ≤3 days) from the intended date. To determine the impact of the RDI of 5-FU, oxaliplatin and irinotecan on survival, the patients were separated into high RDI (>70%) group and low RDI (≤ 70%) group. PFS and OS were measured using Kaplan–Meier and Cox proportional hazard models.
Results
There were 211 patients with chemotherapy dose delay (dose delay >3 days). PFS of patients without dose delay had better survival than patients with dose delay (p<0.01). PFS were better in patients with high RDI of 5-FU than in patients with low RDI (p<0.01). While, there was no statistical difference in OS between the two groups. Moreover, similar result were also shown in patients using oxaliplatin (p = 0.01), rather than irinotecan. Then we stratified the analysis by nutritional status. In patients without nutritional risk (NRS2002 0-2), PFS were better in patients with high RDI of 5-FU or oxaliplatin compared to those with low RDI (p values of 0.01 and <0.01).
Conclusions
In the advanced colorectal cancer patients received 5-FU-based regime as first-line chemotherapy, chemotherapy dose delay and low RDI of 5-FU or oxaliplatin were associated with worse PFS than irinotecan, especially among patients without nutritional risk.
Legal entity responsible for the study
Jinhua Hospital, Zhejiang University School of Medicine.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.